STOCK TITAN
  1. Home
  2. News
  3. SLP

Simulations Plus Inc. - SLP STOCK NEWS

Welcome to our dedicated news page for Simulations Plus (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Simulations Plus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Simulations Plus's position in the market.

News
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
Rhea-AI Summary
Simulations Plus, Inc. (NASDAQ: SLP) reported Q1 fiscal 2024 financial results, with total revenue of $14.5 million, a 21% increase. Software revenue increased 25% to $7.6 million, and services revenue increased 17% to $6.9 million. Adjusted EBITDA was $3.4 million, and net income was $1.9 million with diluted EPS of $0.10. The company maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
earnings
-
News
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces key leadership changes effective January 3, 2024, including the appointment of a new Chief Operating Officer, Chief Revenue Officer, Senior Vice President of Operations, and President of Regulatory Strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
News
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. A conference call will be hosted by management at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast or access the call through dial-in or webcast replay on the investor relations page of the Simulations Plus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
earnings
News
Simulations Plus Outlines Paths to Win at 2023 Investor Day
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) to Host Virtual Investor Day, Reiterates 2024 Guidance. CEO Shawn O’Connor highlights the client-centric business model and new organizational structure driving growth and innovation. Fiscal 2024 guidance includes a 10-15% revenue increase and 35-39% annual increase in diluted earnings per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
none
-
News
ISoP New Board of Trustees Members Announced
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces Amparo de la Peña, Vice President of Pharmacometrics, elected to the International Society of Pharmacometrics (ISoP) Board of Trustees. Three other Trustees also elected. Jill Fiedler-Kelly, President of Clinical Pharmacology & Pharmacometrics at Simulations Plus, praises Amparo's experience and leadership qualities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none
-
News
Simulations Plus to Host Investor Day on Tuesday, November 14th
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will hold a virtual Investor Day on November 14, 2023. CEO Shawn O’Connor and the leadership team will discuss customer-driven growth and innovation. Attendance is by invitation only. Dial-in information will be provided later. Webcast, replay, and transcript will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
conferences
News
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
Rhea-AI Summary
Simulations Plus reports fiscal 2023 revenue of $59.6 million, provides guidance for fiscal 2024 with revenue expected to reach $66-69 million (+10-15%) and EPS of $0.66-0.68. The company's fourth quarter revenue increased 33% YoY, with software revenue up 59% to $9.3 million. Gross profit increased 35% to $12.3 million. Simulations Plus will host its Investor Day on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.7%
Tags
earnings
-
News
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
Rhea-AI Summary
Simulations Plus to report Q4 and fiscal 2023 financial results on October 25, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
earnings
-
News
Simulations Plus Receives New FDA Grant Award
Rhea-AI Summary
Simulations Plus, Inc. has been awarded a new grant from the FDA to validate and define best practices for physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling workflows. The goal is to inform regulatory decisions and guide drug developers in the design of virtual bioequivalence studies. This collaboration is expected to shape industry best practices and reduce regulatory burden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
News
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
Rhea-AI Summary
Simulations Plus completes successful University+ PBPK Summer Camp, with over 80 attendees from 26 countries earning certificates of completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Stock SLP logo
Simulations Plus Inc.

Nasdaq:SLP

SLP Rankings

#2473 Ranked by Market Cap
#3207 Ranked by Stock Gains
#1993 Ranked by Dividends

SLP Stock Data

929.70M
16.19M
18.89%
78.83%
6.01%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
US
Lancaster

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res